Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …

Summary Coronavirus disease 2019 (COVID-19) exhibits variable symptom severity ranging
from asymptomatic to life-threatening, yet the relationship between severity and the humoral …

SARS-CoV-2 infection results in viral burden in the respiratory tract, enabling transmission
and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody …

Broadly neutralizing antibodies (bnAbs) to coronaviruses (CoVs) are valuable in their own
right as prophylactic and therapeutic reagents to treat diverse CoVs and as templates for …

Rapid and specific antibody testing is crucial for improved understanding, control, and
treatment of COVID-19 pathogenesis. Herein, we describe and apply a rapid, sensitive, and …

Abstract Development of antibody protection during SARS-CoV-2 infection is a pressing
question for public health and for vaccine development. We developed highly sensitive …

Background LY-CoV555, a neutralizing monoclonal antibody, has been associated with a
decrease in viral load and the frequency of hospitalizations or emergency department visits …

Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome
(SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody
neutralization response and its evasion by emerging viral variants and variant of concern …